ArticleWorld journal of cardiology2026
Melatonin regulates Sirt1/Nrf2/GPX4 pathway to inhibit ferroptosis and alleviate myocardial injury caused by sepsis.
Article in World journal of cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis, a common and severe infectious disease, remains one of the leading causes of mortality among patients, with myocardial injury representing a major contributor to adverse outcomes. Melatonin, an endogenous hormone, is known to regulate oxidative stress and inflammatory responses; however, its specific role in sepsis-induced myocardial injury remains unclear.
aimTo investigate the protective effects of melatonin on sepsis-induced myocardial injury and to elucidate the underlying mechanisms with a focus on the sirtuin 1/nuclear factor erythroid 2-related factor 2/glutathione peroxidase 4 pathway.
methodsMale 57BL/6 mice were assigned to four groups: (1) The control group; (2) The lipopolysaccharide (LPS) group (15 mg/kg); (3) The LPS plus ferrostatin-1 group (ferroptosis inhibitor, 5 mg/kg); and (4) The LPS plus melatonin group (10 mg/kg). Cardiac function, myocardial injury, biochemical markers, and protein expression levels were evaluated using echocardiography, hematoxylin and eosin staining, biochemical assay kits, western blotting, and the cell counting kit-8 assay. To further investigate the effects of melatonin
resultsEchocardiography and histological evaluation revealed significant impairments in cardiac function and marked myocardial tissue damage in the LPS group, whereas these pathological changes were alleviated in the LPS plus melatonin group. Treatment with melatonin significantly reduced serum levels of brain natriuretic peptide, lactate dehydrogenase, creatine kinase-MB, and cardiac troponin I, while improving myocardial reactive oxygen species and glutathione levels as well as superoxide dismutase activity compared with the LPS group. Protein expression analysis demonstrated an increase in glutathione peroxidase 4 and a decrease in NADPH oxidase 4 and acyl-CoA synthetase long-chain family member 4, consistent with reduced oxidative stress and ferroptosis. In addition, cell viability assays confirmed that melatonin effectively protected HL-1 cardiomyocytes from LPS-induced cytotoxicity.
conclusionThe findings indicate that melatonin alleviates sepsis-induced myocardial injury by inhibiting ferroptosis through regulation of the sirtuin 1/nuclear factor erythroid 2-related factor 2/glutathione peroxidase 4 pathway, providing evidence supporting the potential use of melatonin in the treatment of sepsis-related myocardial injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.